EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 Enrollment ongoing in Phase 1 trial extension cohort 4 exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period; Phase 2 trial on track to initiate before end of ye ...